CPT code 80307: Drug screen, chemistry analyzer2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Presumptive drug screening performed with a chemistry analyzer is reported once per date of service, regardless of the number of classes screened.
Medicare pays $62.14 for 80307 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$62.14
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 80307 covers
This service screens a specimen for the presence of drugs using a chemistry analyzer. The analytical approach may use immunoassay, chromatography, or mass spectrometry, with or without chromatography. It provides a presumptive result rather than the definitive identification associated with targeted testing. Physicians may order the screen in settings such as primary care, pain management, and substance-use treatment; clinical laboratories and offices with testing capability perform it.
Report one unit per date of service, whether the work involves one or several drug classes, devices, or procedures. Sample validation is included when performed. Medicare pays the test through the Clinical Laboratory Fee Schedule (CLFS), not the physician fee schedule. The 2026 national CLFS amount is $62.14, unchanged since 2020. The same amount applies across localities, without an office or facility payment difference.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 80307
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 80307. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 80307 with status X (excluded by statute), so the test itself is paid only from the CLFS.
80307 on the lab fee schedule since 2020
80307 · CLFS 2026 Q4 (current)
$62.14
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
80307 compared with similar tests
- 80305Drug screenDirect optical read$12.60
- 80305 applies to presumptive testing by direct optical observation. Use 80307 when testing is performed by a chemistry analyzer.
- 80306Drug screenInstrument-assisted optical read$17.14
- 80306 applies to presumptive testing by instrument-assisted direct optical observation. 80307 is for chemistry analyzer testing.
- 80324Amphetamine testing1 or 2 substancesNo national amount
- 80324 is for definitive testing of one or two amphetamine drug classes; 80307 reports presumptive screening by chemistry analyzer and may cover any number of drug classes.
80307 billing questions
How does 80307 differ from 80305 and 80306?
Choose among these presumptive drug-screen codes based on the testing approach. 80305 uses direct optical observation, 80306 uses instrument-assisted direct optical observation, and 80307 uses a chemistry analyzer.
How many units are reported when several drug classes are screened?
Report one unit per date of service, regardless of the number of classes, devices, or procedures used.
Is sample validation separately reported?
Sample validation is included in 80307 when performed; it does not create an additional unit of this code.
How does Medicare pay for 80307?
Medicare pays 80307 through the CLFS. The national amount is the same across localities and does not vary between office and facility settings.
How does 80324 differ from 80307?
80324 is for definitive testing of one or two amphetamine drug classes. 80307 reports presumptive screening by chemistry analyzer and may cover any number of drug classes.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets
Put 80307 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Build my fee sheet